LOAMU
PCVX icon

Lombard Odier Asset Management (USA)’s Vaxcyte PCVX Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,427
Closed -$556K – 371
2025
Q3 		$556K Buy
15,427
+1,981
+15% +$65.6K 0.04% 219
2025
Q2 		$437K Buy
+13,446
New +$441K 0.03% 205

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s PCVX Position: Q4 2025 in Review

Lombard Odier Asset Management (USA) sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 15,427 shares — an estimated $556K sold.

Lombard Odier Asset Management (USA) first reported a position in PCVX in Q2 2025 and held it in 2 quarters. The position peaked at $556K in Q3 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Lombard Odier Asset Management (USA) reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 15,427 Vaxcyte shares in Q4 2025, an estimated $556K.
  • Lombard Odier Asset Management (USA) first reported a position in Vaxcyte in Q2 2025 and held it in 2 quarters.
  • Lombard Odier Asset Management (USA)'s Vaxcyte position peaked at $556K in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q4 2025, filed 17 Feb 2026.